Status:
TERMINATED
Antibiotic Prophylaxis for TEVAR
Lead Sponsor:
First Affiliated Hospital of Zhejiang University
Conditions:
Aortic Dissection
Aortic Diseases
Eligibility:
All Genders
Brief Summary
The infection rate of thoracic endovascular aortic repair (TEVAR) is unknown due to a lack of epidemiological data. The rate currently available comes from researches conducted decades ago, when open ...
Eligibility Criteria
Inclusion
- Diagnosed with thoracic aortic diseases
- Received TEVAR
Exclusion
- Suspected infectious aortic disease, such as a mycotic aneurysm.
- TEVAR combined with open surgery
- Antibiotics have been used more than 24 hours before the operation
- Combined with immune deficiency disease or using hormone or immunosuppressant；
- The treatment is for the complications of TEVAR, such as endoleak
- Endovascular aortic repair for abdominal aortic disease
- History of open aortic surgery or heart surgery.
- Revascularization of visceral arteries during the TEVAR
Key Trial Info
Start Date :
January 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2025
Estimated Enrollment :
457 Patients enrolled
Trial Details
Trial ID
NCT05405790
Start Date
January 1 2022
End Date
September 1 2025
Last Update
September 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital, College of Medicine, Zhejiang University
Hanzhou, Zhejiang, China